

## List of Supporting Information:

**Supplementary Table S1.** Primers Related to RT-PCR, and Short Hairpin Plasmids Construction.

**Supplementary Table S2.** Primary antibody used in the study.

**Supplementary Table S3.** Correlation between CXCR6 IHC expression levels and clinicopathological features in patients with gastric cancer.

**Supplementary Table S4.** Multivariate analysis of prognostic parameters in patients with gastric cancer by Cox regression analysis.

### Supplementary Table S1. Primers related to RT-qPCR, and short hairpin plasmids construction.

Primer set	Primers	Sequence
<b>RT-qPCR</b>		
CXCL16	F	5'- AAAGAGCTCACTCGTCCCAA-3'
	R	5'- CAAGCTTCCATTCTTGGCTC-3'
GAPDH	F	5'-GGGCTGCTTTTAACTCTGGT-3'
	R	5'-TGATTTTGGAGGGATCTCGC-3'
<b>Knocking down target sequence</b>		
CXCL16	sh1	5'- CUCACUCGUCCCAAUGAAATT-3'
	sh2	5'- GGAUCACUGUCCUCGGACATT-3'
ADDAM10	sh1	5'- GGGTCTGTTATTGATGGAAGA-3'
	sh2	5'- GCTGATGAGAA GGACCCTACA-3'

**Supplementary Table S2. Primary antibody used in the study.**

<b>Primary antibody</b>	<b>Catalog</b>	<b>Company</b>
$\beta$ -Catenin(D10A8)	#8480S	Cell Signaling Technology
E-Cadherin	#3195	Cell Signaling Technology
N-Cadherin	#13116	Cell Signaling Technology
Phospho-p38 MAPK	#8690S	Cell Signaling Technology
Phospho-p38 MAPK (Thr180/Tyr182)	#9211S	Cell Signaling Technology
p44/MAPK (Erk1/2)	#4695S	Cell Signaling Technology
Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204)	#9101	Cell Signaling Technology
Akt (pan) (C67E7)	#9272	Cell Signaling Technology
Phospho-Akt (Ser473)	#4060	Cell Signaling Technology
Slug	#9585T	Cell Signaling Technology
Snail (C15D3)	#3879	Cell Signaling Technology
ZO-1	#5406	Cell Signaling Technology
CXCL16	ab101404	Abcam
ADAM10	ab1997	Abcam
CXCR6	ab8023	Abcam
GAPDH	60004-1-IG	Proteintech

**Supplementary Table S3. Correlation between CXCR6 IHC expression levels and clinicopathological features in patients with gastric cancer.**

Characteristics	Number (n=55)	Expression of CXCR6		P value
		Negative (%)	Positive (%)	
<b>Gander</b>				
Male	36	8 (53.5)	29 (72.5)	0.068
Female	19	7 (46.7)	11 (27.5)	
<b>Age (y)</b>				
≤60	32	9 (60.0)	23 (57.5)	0.729
>60	23	6 (40.0)	17 (42.5)	
<b>Diameter (cm)</b>				
≤5cm	35	10 (66.7)	25 (67.6)	0.950
>5cm	17	5 (33.3)	12 (32.4)	
<b>Pathological types</b>				
Adenocarcinoma	45	12 (80.0)	33 (82.5)	0.832
others	10	3 (20.0)	7 (17.5)	
<b>Histologic differentiation</b>				
Well or moderate	45	15(100.0)	30 (75.0)	<b>0.034*</b>
Poor	10	0 (0.0)	10 (25.0)	
<b>Depth of invasion</b>				
T1-2	14	7 (46.7)	7 (17.9)	<b>0.033*</b>
T3-4	40	8 (53.3)	32 (82.1)	
<b>Lymphatic metastasis</b>				
No	13	4 (26.7)	9 (22.5)	0.748
Yes	42	11 (73.3)	31 (77.5)	
<b>Distant metastasis</b>				
M0	51	15 (100.0)	36 (92.3)	0.274
M1	3	0 (0.0)	3 (7.7)	
<b>pTNM stage</b>				
I-II	15	6 (40.0)	9 (22.5)	0.198
III-IV	40	9 (60.0)	31 (77.5)	

Note: \* $P < 0.05$ .

**Supplementary Table S4. Multivariate analysis of prognostic parameters in patients with gastric cancer by Cox regression analysis.**

Prognostic parameters	Multivariate analysis		P-value
	HR	95%CI	
Gander			
Male	2.219	0.818-6.020	0.118
Female			
Age (years)			
≤60	3.284	1.281-8.418	<b>0.013*</b>
>60			
Histologic differentiation			
Well or moderate	0.185	0.039-0.887	<b>0.035*</b>
Poor			
CXCR6 expression			
Negative	1.945	0.550-6.872	0.302
Positive			

**Note:** \* $P < 0.05$ .

Abbreviations: HR, hazard ratio; CI, confidence interval.